Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — Shareholder Meeting (August 2019)
30 slides from Aft Pharmaceuticals's shareholder meeting presentation, Aug 2, 2019
Slide 1: Annual Shareholders Meeting
For personal use only Working to improve your health Annual Shareholders Meeting 2 August 2019
Slide 2: Important Notice
Important Notice For personal use only This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New
Slide 3: Chairman's Introduction
CHAIRMAN’S INTRODUCTION For personal use only ASM AUG 2019 David Flacks 3
Slide 4: Directors and Executives Introductions
For personal use only DIRECTORS AND EXECUTIVES INTRODUCTIONS ASM AUG 2019 4
Slide 5: Agenda
AGENDA For personal use only Chairman’s address Chief Executive Officer’s Presentation Shareholder Questions Ordinary Resolutions Special Resolution ASM AUG 2019 5
Slide 6: FY 2019 Highlights
FY 2019 Highlights For personal use only 42 countries Maxigesic registered in 20 countries Maxigesic launched in $85.1m operating revenue for FY2019 $6.1m operating profit and $16.2m improvement on FY2018 $6.9m available cash as at 31 March 2019 – up from $6.7m end of FY2018 ASM AUG 2019 6
Slide 7: Product development, Balance sheet and funding, Governance
For personal use only Product development Balance sheet and funding Governance ASM AUG 2019 7
Slide 8: CEO's Presentation
CEO’s PRESENTATION For personal use only ASM AUG 2019 Hartley Atkinson 8
Slide 9: Revenue Growth
Revenue Growth For personal use only 10 year operating CAGR of 13% Operating revenue (NZ$m) FY2018 FY2019 Australia ASM AUG 2019 New Zealand Rest of World Southeast Asia 9
Slide 10: Financial performance - Revenue by region and channel
Financial performance - Revenue by region and channel For personal use only NZ$000’s FY2017 % of total FY2018 % of total FY2019 % of total Australia 37,063 53.6% 49,193 60.6% 50,304 59.1% YoY growth 32.7% 2.3%/12.6% New Zealand 29,167 42.1% 27,096 33.4% 26,796 31.5% YoY growth -7.1% -1.1%/5.4% Rest
Slide 11: Profit and Loss
Profit and Loss For personal use only NZ$'000's year ended 31 March 2019 % of 2018 % of revenue revenue Revenue 85,127 81,176 Cost of Sales (44,397) 52.2% (45,880) 56.5% Gross Profit 40,730 47.8% 35,296 43.5% Other Income 2,237 2.6% 1,130 1.4% Selling and distribution expenses (26,540) 31.2% (28,533
Slide 12: Balance Sheet
Balance Sheet For personal use only NZ$'000's year ended 31 March 2019 2018 Current Assets 51,261 48,312 Non Current Assets 12,334 8,291 Total Assets 63,595 56,603 Current Liabilities 58,504 18,607 Non Current Liabilities - 30,654 Total Liabilities 58,504 49,261 Equity 5,091 7,342 Total Liabilities
Slide 13: Cashflow
Cashflow For personal use only NZ$'000's year ended 31 March 2019 2018 Net cash used in operating activities 1,067 (9,167) Net cash used in investing activities (4,884) (5,855) Net cash generated from financing activities 3,723 5,863 Net increase in cash (94) (9,159) Impact of foreign exchange on ca
Slide 14: Operating profit progress
Operating profit progress 15 For personal use only 10 5 0 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 (5) (10) ASM AUG 2019 (15) 14
Slide 15: Selling date dependent on successful R&D and registration
For personal use only ASM AUG 2019 Selling date dependent on successful R&D and registration 15
Slide 16: Maxigesic Development Progress
Maxigesic Development Progress For personal use only Maxigesic Tablets • registered across all of EU Maxigesic IV • first registration achieved 2019 in AU • sales predicted to start late 2019/2020 Maxigesic Oral Liquid • filings in 23 countries • sales anticipated to start 2020 Maxigesic Hot Drink S
Slide 17: Maxigesic Countries sold and ordered
Maxigesic Countries sold and ordered For personal use only ASM AUG 2019 17
Slide 18: Maxigesic Global Update
For personal use only MAXIGESIC GLOBAL UPDATE [primarily oral dose forms] Lconsed in Russia A Launched 6 Launch Pending A hrailable
Slide 19: Maxigesic going forward
Maxigesic going forward For personal use only Product Maxigesic Tablets Maxigesic IV Maxigesic oral solution Territories 2019 2018 2019 2018 2019 2018 Licensed 125+ 125 -% 68 62 10% 122 118 4% Registered 42 32 28% 1 - + +% - - -% Sold in 20 10 100% - - -% - - -% ASM AUG 2019 19
Slide 20: Pascomer development
Pascomer development For personal use only Market - 30,000 patients in US alone represents a US$300m market opportunity Knowledge – 12 published trials and published case reports on 425 patients using compounded rapamycin show that it successfully treats the condition Pascomer development – two tria
Slide 21: Medium Term Plans
Medium Term Plans For personal use only Further drive International Sales - Accelerate countries launched in - Start to launch new line extensions [Maxigesic IV] Extend International Licensing - Achieve licensing agreement in USA/Canada, Germany and LATAM - Explore previously unplanned territories:
Slide 22: Questions and Answers
For personal use only ASM AUG 2019 22 ANSWERS QUESTIONS AND
Slide 23: Resolutions
For personal use only ASM AUG 2019 23 Resolutions
Slide 24: Ordinary Resolution 1
For personal use only Ordinary Resolution 1 1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2020 financial year. ASM AUG 2019 24
Slide 25: Ordinary Resolution 2
For personal use only Ordinary Resolution 2 2. That Dr Hartley Atkinson be re-elected as a director of AFT Pharmaceuticals Limited. ASM AUG 2019 25
Slide 26: Ordinary Resolution 3
For personal use only Ordinary Resolution 3 3. That Mr Jon Lamb be re-elected as a director of AFT Pharmaceuticals Limited. ASM AUG 2019 26
Slide 27: Ordinary Resolution 4
For personal use only Ordinary Resolution 4 4. That Dr John Douglas Wilson be re-elected as a director of AFT Pharmaceuticals Limited. ASM AUG 2019 27
Slide 28: Special Resolution
For personal use only Special Resolution 5 5. That the existing constitution of the Company is revoked, and the constitution tabled at the meeting, and referred to in the explanatory notes, is adopted as the constitution of the Company. ASM AUG 2019 28
Slide 29: Voting
For personal use only ASM AUG 2019 29 Voting
Slide 30: Close of Meeting
For personal use only Close of Meeting Thanks for attending ASM AUG 2019 30
AFT Pharmaceuticals — Shareholder Meeting (August 2019) on 6ix